Lead candidate Nefecon (a targeted-release budesonide formulation) is positioned, if approved, to transform the treatment of IgAN. Today, the 130,000–150,000 people estimated to suffer from this ...

Nefecon is a formulation of the established immunology drug budesonide, which targets the Peyer’s patches that are over-active in patients with IgAN. The antibodies produced as a result lodge in ...

Nefecon takes the form of an encapsulated oral formulation of the established corticosteroid budesonide, which Calliditas says provides localised delivery of the drug to the ileum in the ...